Advanced Breast Cancer Clinical Trials in Fairfax, Virginia

5 studies are recruiting for advanced breast cancer in Fairfax, Virginia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Virginia Cancer Specialists, PC, Fairfax, Virginia

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

2. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

   This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   45 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06638307 on ClinicalTrials.gov

3. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

   This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT Virginia, Fairfax, Virginia

   Locations

   5 in total

   Run by

   Regor Pharmaceuticals Inc.

   See if you can join NCT07524322 on ClinicalTrials.gov

4. Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

   Phase 1/2, open-label study of ETX-636 in participants with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT, Fairfax, Virginia

   Locations

   15 in total

   Run by

   Ensem Therapeutics

   See if you can join NCT06993844 on ClinicalTrials.gov

5. First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

   This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, cataly…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Inova Schar Cancer Center, Fairfax, Virginia

   Locations

   37 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT05216432 on ClinicalTrials.gov